Jian Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jian Wen has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Hefeng Xu
School of Intelligent Medicine, China Medical University, Shenyang, China
2 shared publicationsLinxuan Wu
School of Intelligent Medicine, China Medical University, Shenyang, China
2 shared publications- Max S. Wicha
Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA
2 shared publications - Ming Luo
Department of Breast and Thyroid Surgery, Peking University Shenzhen Hospital, Shenzhen 518036, China
2 shared publications - Minjie Wei
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
2 shared publications - Xiaoqian Xu
Department of Developmental Cell Biology Key Laboratory of Cell Biology Ministry of Public Health and Key Laboratory of Medical Cell Biology Ministry of Education China Medical University Shenyang China
2 shared publications
Latest Publications
- Open Access
Long Non-Coding RNAs: Key Regulators of Tumor Epithelial/Mesenchymal Plasticity and Cancer Stemness
Long non-coding RNAs (lncRNAs) are a class of non-coding RNA molecules with transcripts longer than 200 bp, which were initially thought to be noise from genomic transcription without biological function. However, since the discovery of H19 in 1980 and Xist in 1990, increasing evidence has shown that lncRNAs regulate gene expression at epigenetic, transcriptional, and post-transcriptional levels through specific regulatory actions and are involved in the development of cancer and other diseases. Despite many lncRNAs being expressed at lower levels than those of protein-coding genes with less sequence conservation across species, lncRNAs have become an intense area of RNA research. They exert diverse biological functions such as inducing chromatin remodeling, recruiting transcriptional machinery, acting as competitive endogenous RNAs for microRNAs, and modulating protein–protein interactions. Epithelial–mesenchymal transition (EMT) is a developmental process, associated with embryonic development, wound healing, and cancer progression. In the context of oncogenesis, the EMT program is transiently activated and confers migratory/invasive and cancer stem cell (CSC) properties to tumor cells, which are crucial for malignant progression, metastasis, and therapeutic resistance. Accumulating evidence has revealed that lncRNAs play crucial roles in the regulation of tumor epithelial/mesenchymal plasticity (EMP) and cancer stemness. Here, we summarize the emerging roles and molecular mechanisms of lncRNAs in regulating tumor cell EMP and their effects on tumor initiation and progression through regulation of CSCs. We also discuss the potential of lncRNAs as diagnostic and prognostic biomarkers and therapeutic targets.
Open AccessLong Non-Coding RNAs: Key Regulators of Tumor Epithelial/Mesenchymal Plasticity and Cancer Stemness
Long non-coding RNAs (lncRNAs) are a class of non-coding RNA molecules with transcripts longer than 200 bp, which were initially thought to be noise from genomic transcription without biological function. However, since the discovery of H19 in 1980 and Xist in 1990, increasing evidence has shown that lncRNAs regulate gene expression at epigenetic, transcriptional, and post-transcriptional levels through specific regulatory actions and are involved in the development of cancer and other diseases. Despite many lncRNAs being expressed at lower levels than those of protein-coding genes with less sequence conservation across species, lncRNAs have become an intense area of RNA research. They exert diverse biological functions such as inducing chromatin remodeling, recruiting transcriptional machinery, acting as competitive endogenous RNAs for microRNAs, and modulating protein–protein interactions. Epithelial–mesenchymal transition (EMT) is a developmental process, associated with embryonic development, wound healing, and cancer progression. In the context of oncogenesis, the EMT program is transiently activated and confers migratory/invasive and cancer stem cell (CSC) properties to tumor cells, which are crucial for malignant progression, metastasis, and therapeutic resistance. Accumulating evidence has revealed that lncRNAs play crucial roles in the regulation of tumor epithelial/mesenchymal plasticity (EMP) and cancer stemness. Here, we summarize the emerging roles and molecular mechanisms of lncRNAs in regulating tumor cell EMP and their effects on tumor initiation and progression through regulation of CSCs. We also discuss the potential of lncRNAs as diagnostic and prognostic biomarkers and therapeutic targets.
- Open Access
- 4 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (8) , e2413607
Hydrogen Sulfide Promotes TAM‐M1 Polarization through Activating IRE‐1α Pathway via GRP78 S‐Sulfhydrylation to against Breast Cancer
Hydrogen sulfide (H2S)‐mediated protein S‐sulfhydration has been shown to play critical roles in several diseases. Tumor‐associated macrophages (TAMs) are the predominant population of immune cells present within solid tumor tissues, and they function to restrict antitumor immunity. However, no previous study has investigated the role of protein S‐sulfhydration in TAM reprogramming in breast cancer (BC). Therefore, the aim is to investigate whether protein S‐sulfhydration can regulate TAM reprogramming and its underlying mechanism in BC. The results showed that in BC, the CTH‐H2S axis is positively correlated with the presence of an anti‐tumor phenotype in TAMs. NaHS, as an H2S donor, repolarized TAMs into M1 macrophages to block the tumor‐promoting activities of TAMs both in vitro and in vivo. Mechanistically, H2S‐mediated S‐sulfhydration of the protein chaperone glucose‐regulated‐protein 78 (GRP78) induced endoplasmic reticulum transmembrane protein kinase‐1α (IRE‐1α) dissociation from GRP78, which enhanced the phosphatase activity of IRE‐1α itself in BC‐TAMs, while the Cys420 site mutation of GRP78 interfered with these effects. Collectively, GRP78 S‐sulfhydrylation mediated by H2S at the Cys420 residue decreased the tumor burden and inhibited lung metastasis of BC through reprograming TAMs via activating the IRE‐1α pathway, indicating that targeting GRP78 S‐sulfhydration represents a promising intervention for TAM‐M1 repolarization in BC.
- 4 January 2025
- Published by Wiley in Advanced Science
- Vol. 12 (8) , e2413607
Open AccessHydrogen Sulfide Promotes TAM‐M1 Polarization through Activating IRE‐1α Pathway via GRP78 S‐Sulfhydrylation to against Breast Cancer
Hydrogen sulfide (H2S)‐mediated protein S‐sulfhydration has been shown to play critical roles in several diseases. Tumor‐associated macrophages (TAMs) are the predominant population of immune cells present within solid tumor tissues, and they function to restrict antitumor immunity. However, no previous study has investigated the role of protein S‐sulfhydration in TAM reprogramming in breast cancer (BC). Therefore, the aim is to investigate whether protein S‐sulfhydration can regulate TAM reprogramming and its underlying mechanism in BC. The results showed that in BC, the CTH‐H2S axis is positively correlated with the presence of an anti‐tumor phenotype in TAMs. NaHS, as an H2S donor, repolarized TAMs into M1 macrophages to block the tumor‐promoting activities of TAMs both in vitro and in vivo. Mechanistically, H2S‐mediated S‐sulfhydration of the protein chaperone glucose‐regulated‐protein 78 (GRP78) induced endoplasmic reticulum transmembrane protein kinase‐1α (IRE‐1α) dissociation from GRP78, which enhanced the phosphatase activity of IRE‐1α itself in BC‐TAMs, while the Cys420 site mutation of GRP78 interfered with these effects. Collectively, GRP78 S‐sulfhydrylation mediated by H2S at the Cys420 residue decreased the tumor burden and inhibited lung metastasis of BC through reprograming TAMs via activating the IRE‐1α pathway, indicating that targeting GRP78 S‐sulfhydration represents a promising intervention for TAM‐M1 repolarization in BC.
- Open Access
- 26 December 2024
- Published by MDPI AG in Preprints.org
Long Non-coding RNAs: Key Regulators of Tumor Epithelial/Mesenchymal Plasticity and Cancer Stemness
Long non-coding RNAs (lncRNAs) are a class of non-coding RNA molecules with transcripts longer than 200bp, which were initially thought to be noise from genomic transcription without biological function. However, since the discovery of H19 in 1980 and Xist in 1990, increasing evidence has shown that lncRNAs regulate gene expression at epigenetic, transcriptional and post-transcriptional levels through specific regulatory actions, and are involved in the development of cancer and other diseases. Despite lower abundance of lncRNAs than that of protein-coding genes with less sequence conservation, lncRNAs have become an intense area of RNA research. They exert diverse biological functions such as inducing chromatin remodeling, recruiting the transcriptional machinery, acting as competitive endogenous RNAs for microRNAs, and modulating protein-protein interactions. Epithelial-mesenchymal transition (EMT) is a developmental process, associated with embryonic development, wound healing, and cancer progression. In the context of oncogenesis, the EMT program is transiently activated and confers migratory/invasive and cancer stem cell (CSC) properties to tumor cells, which are crucial for malignant progression, metastasis, and therapeutic resistance. Accumulating evidence has revealed that lncRNAs play crucial roles in the regulation of tumor epithelial/mesenchymal plasticity (EMP) and cancer stemness. Here, we summarize the emerging roles and molecular mechanisms of lncRNAs in regulating tumor cell EMP and their effects on tumor initiation and progression through regulation of CSCs. We also discuss the potential of lncRNAs as diagnostic and prognostic biomarkers and therapeutic targets.
- 26 December 2024
- Published by MDPI AG in Preprints.org
Open AccessLong Non-coding RNAs: Key Regulators of Tumor Epithelial/Mesenchymal Plasticity and Cancer Stemness
Long non-coding RNAs (lncRNAs) are a class of non-coding RNA molecules with transcripts longer than 200bp, which were initially thought to be noise from genomic transcription without biological function. However, since the discovery of H19 in 1980 and Xist in 1990, increasing evidence has shown that lncRNAs regulate gene expression at epigenetic, transcriptional and post-transcriptional levels through specific regulatory actions, and are involved in the development of cancer and other diseases. Despite lower abundance of lncRNAs than that of protein-coding genes with less sequence conservation, lncRNAs have become an intense area of RNA research. They exert diverse biological functions such as inducing chromatin remodeling, recruiting the transcriptional machinery, acting as competitive endogenous RNAs for microRNAs, and modulating protein-protein interactions. Epithelial-mesenchymal transition (EMT) is a developmental process, associated with embryonic development, wound healing, and cancer progression. In the context of oncogenesis, the EMT program is transiently activated and confers migratory/invasive and cancer stem cell (CSC) properties to tumor cells, which are crucial for malignant progression, metastasis, and therapeutic resistance. Accumulating evidence has revealed that lncRNAs play crucial roles in the regulation of tumor epithelial/mesenchymal plasticity (EMP) and cancer stemness. Here, we summarize the emerging roles and molecular mechanisms of lncRNAs in regulating tumor cell EMP and their effects on tumor initiation and progression through regulation of CSCs. We also discuss the potential of lncRNAs as diagnostic and prognostic biomarkers and therapeutic targets.
- Open Access
- 25 June 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-34
Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials
Locally advanced breast cancer (LABC) is a heterogeneous group of breast cancer that accounts for 10–30% of breast cancer cases. Despite the ongoing development of current treatment methods, LABC remains a severe and complex public health concern around the world, thus prompting the urgent requirement for innovative diagnosis and treatment strategies. The primary treatment challenges are inoperable clinical status and ineffective local control methods. With the rapid advancement of nanotechnology, inorganic nanoparticles (INPs) exhibit a potential application prospect in diagnosing and treating breast cancer. Due to the unique inherent characteristics of INPs, different functions can be performed via appropriate modifications and constructions, thus making them suitable for different imaging technology strategies and treatment schemes. INPs can improve the efficacy of conventional local radiotherapy treatment. In the face of inoperable LABC, INPs have proposed new local therapeutic methods and fostered the evolution of novel strategies such as photothermal and photodynamic therapy, magnetothermal therapy, sonodynamic therapy, and multifunctional inorganic nanoplatform. This article reviews the advances of INPs in local accurate imaging and breast cancer treatment and offers insights to overcome the existing clinical difficulties in LABC management. Graphical Abstract
- 25 June 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-34
Open AccessDiagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials
Locally advanced breast cancer (LABC) is a heterogeneous group of breast cancer that accounts for 10–30% of breast cancer cases. Despite the ongoing development of current treatment methods, LABC remains a severe and complex public health concern around the world, thus prompting the urgent requirement for innovative diagnosis and treatment strategies. The primary treatment challenges are inoperable clinical status and ineffective local control methods. With the rapid advancement of nanotechnology, inorganic nanoparticles (INPs) exhibit a potential application prospect in diagnosing and treating breast cancer. Due to the unique inherent characteristics of INPs, different functions can be performed via appropriate modifications and constructions, thus making them suitable for different imaging technology strategies and treatment schemes. INPs can improve the efficacy of conventional local radiotherapy treatment. In the face of inoperable LABC, INPs have proposed new local therapeutic methods and fostered the evolution of novel strategies such as photothermal and photodynamic therapy, magnetothermal therapy, sonodynamic therapy, and multifunctional inorganic nanoplatform. This article reviews the advances of INPs in local accurate imaging and breast cancer treatment and offers insights to overcome the existing clinical difficulties in LABC management. Graphical Abstract
- 21 November 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (48) , 11519-11531
All-in-one HN@Cu-MOF nanoparticles with enhanced reactive oxygen species generation and GSH depletion for effective tumor treatment
Non-invasive cancer therapies, especially those based on reactive oxygen species, including photodynamic therapy (PDT), have gained much interest. As emerging photodynamic nanocarriers, metal–organic frameworks (MOFs) based on porphyrin can release reactive oxygen species (ROS) to destroy cancer cells. However, due to the inefficient production of ROS by photosensitizers and the over-expression of glutathione (GSH) in the tumor microenvironment (TME), their therapeutic effect is not satisfactory. Therefore, herein, we developed a multi-functional nanoparticle, HN@Cu-MOF, to enhance the efficacy of PDT. We combined chemical dynamic therapy (CDT) and nitric oxide (NO) therapy by initiating sensitization to PDT and cell apoptosis in the treatment of tumors. The Cu2+-doped MOF reacted with GSH to form Cu+, exhibiting a strong CDT ability to generate hydroxyl radicals (˙OH). The Cu-MOF was coated with HN, which is hyaluronic acid (HA) modified by a nitric oxide donor. HN can target tumor cells over-expressing the CD44 receptor and consume GSH in the cells to release NO. Both cell experiments and in vivo experiments showed an excellent tumor inhibitory effect upon the treatment. Overall, the HN@Cu-MOF nanoparticle-integrated NO gas therapy and CDT with PDT led to a significant enhancement in GSH consumption and a remarkable elevation in ROS production.
- 21 November 2023
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 11 (48) , 11519-11531
All-in-one HN@Cu-MOF nanoparticles with enhanced reactive oxygen species generation and GSH depletion for effective tumor treatment
Non-invasive cancer therapies, especially those based on reactive oxygen species, including photodynamic therapy (PDT), have gained much interest. As emerging photodynamic nanocarriers, metal–organic frameworks (MOFs) based on porphyrin can release reactive oxygen species (ROS) to destroy cancer cells. However, due to the inefficient production of ROS by photosensitizers and the over-expression of glutathione (GSH) in the tumor microenvironment (TME), their therapeutic effect is not satisfactory. Therefore, herein, we developed a multi-functional nanoparticle, HN@Cu-MOF, to enhance the efficacy of PDT. We combined chemical dynamic therapy (CDT) and nitric oxide (NO) therapy by initiating sensitization to PDT and cell apoptosis in the treatment of tumors. The Cu2+-doped MOF reacted with GSH to form Cu+, exhibiting a strong CDT ability to generate hydroxyl radicals (˙OH). The Cu-MOF was coated with HN, which is hyaluronic acid (HA) modified by a nitric oxide donor. HN can target tumor cells over-expressing the CD44 receptor and consume GSH in the cells to release NO. Both cell experiments and in vivo experiments showed an excellent tumor inhibitory effect upon the treatment. Overall, the HN@Cu-MOF nanoparticle-integrated NO gas therapy and CDT with PDT led to a significant enhancement in GSH consumption and a remarkable elevation in ROS production.
- Open Access
- 1 June 2023
- Published by Elsevier in Materials Today Bio
- Vol. 20, 100673
Challenges and advances for glioma therapy based on inorganic nanoparticles
- 1 June 2023
- Published by Elsevier in Materials Today Bio
- Vol. 20, 100673
Open AccessChallenges and advances for glioma therapy based on inorganic nanoparticles
- Open Access
- 20 April 2023
- Published by Springer Nature in BMC Gastroenterology
- Vol. 23 (1) , 1-15
A new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification
Purpose: Hepatocellular carcinoma (HCC) is a kind of primary liver cancer. It is a common malignant tumor of digestive system that is difficult to predict the prognosis of patients. As an important epigenetic modification, N7 methyl guanosine (m7G) is indispensable in gene regulation. This regulation may affect the development and occurrence of cancer. However, the prognosis of long non coding RNAs (lncRNAs) in HCC is limited, especially how m7G-related lncRNAs regulate the development of HCC has not been reported. Methods: The Cancer Genome Atlas (TCGA) provides us with the expression data and corresponding clinical information of HCC patients we need. We used a series of statistical methods to screen four kinds of m7G-related lncRNAs related to HCC prognosis and through a series of verifications, the results were in line with our expectations. Finally, we also explored the IC50 difference and correlation analysis of various common chemotherapy drugs. Result: Our study identified four differentially expressed m7g-related lncRNAs associated with HCC prognosis. Survival curve analysis showed that high risk lncRNAs would lead to poor prognosis of HCC patients. M7G signature's AUC was 0.789, which shows that the prognosis model we studied has certain significance in predicting the prognosis of HCC patients. Moreover, our study found that different risk groups have different immune and tumor related pathways through gene set enrichment analysis. In addition, many immune cell functions are significantly different among different risk groups, such as T cell functions, including coordination of type I INF response and coordination of type II INF response. The expression of PDCD1, HHLA2, CTLA-4 and many other immune checkpoints in different risk groups is also different. Additionally, we analyzed the differences of IC50 and risk correlation of 15 chemotherapeutic drugs among different risk groups. Conclusion: A novel lncRNAs associated with m7G predicts the prognosis of HCC.
- 20 April 2023
- Published by Springer Nature in BMC Gastroenterology
- Vol. 23 (1) , 1-15
Open AccessA new prediction model of hepatocellular carcinoma based on N7-methylguanosine modification
Purpose: Hepatocellular carcinoma (HCC) is a kind of primary liver cancer. It is a common malignant tumor of digestive system that is difficult to predict the prognosis of patients. As an important epigenetic modification, N7 methyl guanosine (m7G) is indispensable in gene regulation. This regulation may affect the development and occurrence of cancer. However, the prognosis of long non coding RNAs (lncRNAs) in HCC is limited, especially how m7G-related lncRNAs regulate the development of HCC has not been reported. Methods: The Cancer Genome Atlas (TCGA) provides us with the expression data and corresponding clinical information of HCC patients we need. We used a series of statistical methods to screen four kinds of m7G-related lncRNAs related to HCC prognosis and through a series of verifications, the results were in line with our expectations. Finally, we also explored the IC50 difference and correlation analysis of various common chemotherapy drugs. Result: Our study identified four differentially expressed m7g-related lncRNAs associated with HCC prognosis. Survival curve analysis showed that high risk lncRNAs would lead to poor prognosis of HCC patients. M7G signature's AUC was 0.789, which shows that the prognosis model we studied has certain significance in predicting the prognosis of HCC patients. Moreover, our study found that different risk groups have different immune and tumor related pathways through gene set enrichment analysis. In addition, many immune cell functions are significantly different among different risk groups, such as T cell functions, including coordination of type I INF response and coordination of type II INF response. The expression of PDCD1, HHLA2, CTLA-4 and many other immune checkpoints in different risk groups is also different. Additionally, we analyzed the differences of IC50 and risk correlation of 15 chemotherapeutic drugs among different risk groups. Conclusion: A novel lncRNAs associated with m7G predicts the prognosis of HCC.
- 7 June 2022
- Published by Springer Nature in The EMBO Journal
- Vol. 41 (14) , e109777
TRIM27 cooperates with STK38L to inhibit ULK1‐mediated autophagy and promote tumorigenesis
Autophagy represents a fundamental mechanism for maintaining cell survival and tissue homeostasis in response to physiological and pathological stress. Autophagy initiation converges on the FIP200‐ATG13‐ULK1 complex wherein the serine/threonine kinase ULK1 plays a central role. Here, we reveal that the E3 ubiquitin ligase TRIM27 functions as a negative regulatory component of the FIP200‐ATG13‐ULK1 complex. TRIM27 directly polyubiquitinates ULK1 at K568 and K571 sites with K48‐linked ubiquitin chains, with proteasomal turnover maintaining control over basal ULK1 levels. However, during starvation‐induced autophagy, TRIM27 catalyzes non‐degradative K6‐ and K11‐linked ubiquitination of the serine/threonine kinase 38‐like (STK38L) kinase. In turn, STK38L ubiquitination promotes its activation and phosphorylation of ULK1 at Ser495, rendering ULK1 in a permissive state for TRIM27‐mediated hyper‐ubiquitination of ULK1. This cooperative mechanism serves to restrain the amplitude and duration of autophagy. Further evidence from mouse models shows that basal autophagy levels are increased in Trim27 knockout mice and that Trim27 differentially regulates tumorigenesis and metastasis. Our study identifies a key role of STK38L‐TRIM27‐ULK1 signaling axis in negatively controlling autophagy with relevance established in human breast cancer.
- 7 June 2022
- Published by Springer Nature in The EMBO Journal
- Vol. 41 (14) , e109777
TRIM27 cooperates with STK38L to inhibit ULK1‐mediated autophagy and promote tumorigenesis
Autophagy represents a fundamental mechanism for maintaining cell survival and tissue homeostasis in response to physiological and pathological stress. Autophagy initiation converges on the FIP200‐ATG13‐ULK1 complex wherein the serine/threonine kinase ULK1 plays a central role. Here, we reveal that the E3 ubiquitin ligase TRIM27 functions as a negative regulatory component of the FIP200‐ATG13‐ULK1 complex. TRIM27 directly polyubiquitinates ULK1 at K568 and K571 sites with K48‐linked ubiquitin chains, with proteasomal turnover maintaining control over basal ULK1 levels. However, during starvation‐induced autophagy, TRIM27 catalyzes non‐degradative K6‐ and K11‐linked ubiquitination of the serine/threonine kinase 38‐like (STK38L) kinase. In turn, STK38L ubiquitination promotes its activation and phosphorylation of ULK1 at Ser495, rendering ULK1 in a permissive state for TRIM27‐mediated hyper‐ubiquitination of ULK1. This cooperative mechanism serves to restrain the amplitude and duration of autophagy. Further evidence from mouse models shows that basal autophagy levels are increased in Trim27 knockout mice and that Trim27 differentially regulates tumorigenesis and metastasis. Our study identifies a key role of STK38L‐TRIM27‐ULK1 signaling axis in negatively controlling autophagy with relevance established in human breast cancer.
- Open Access
- 4 May 2022
- Published by Springer Nature in Research Square
N 7-methylguanosine-related gene risk signature as a potential prognostic biomarker in hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) remains one of the most common malignancies worldwide, with an increasing annual incidence and mortality. N 7-methylguanosine (m7G) is a modification in which a methyl group is added to the seventh N position of messenger ribonucleic acid (RNA) guanine (G) by methylation transferase action. Increasing evidence revealed that m7G-related genes are closely associated with HCC development. This study aimed to develop a new m7G-related prognostic model to assess the prognosis of patients with HCC.Methods: Herein, we used RNA transcriptome sequencing and clinical data of patients with HCC from the Cancer Genome Atlas (TCGA). Patients with HCC were classified into two subtypes based on the m7G gene, and differential expression genes (DEGs) between the two types were identified. Prognostic risk models were constructed by assessing the prognostic significance of these DEGs using univariate Cox, least absolute shrinkage and selection operator, and multivariate Cox regression analyses. Functional differences were compared between the high and low-risk groups and differences in immune infiltration and immunotherapy. Finally, a preliminary pan-cancer analysis of the two genes in the model was performed.Results: Significant survival differences were found between different subtypes of patients with HCC, who were divided into high and low-risk groups according to the median risk scores. The Kaplan–Meier survival analysis showed a substantially better overall survival in the low-risk group than that in the high-risk group (p < 0.001). Receiver operating characteristic curves and within-group validation further confirmed the model’s reliability and accuracy. Additionally, significant differences were found in functional analysis, immune infiltration, and immunotherapy effects between the two groups. GAS2L3 and HTR1D have prognostic value in various cancers, which may help for subsequent studies.Conclusions: In conclusion, this prognostic model based on m7G-related genes is beneficial for individualized prognosis assessment of patients with HCC and provides a reference for clinical treatment.
- 4 May 2022
- Published by Springer Nature in Research Square
Open AccessN 7-methylguanosine-related gene risk signature as a potential prognostic biomarker in hepatocellular carcinoma
Background: Hepatocellular carcinoma (HCC) remains one of the most common malignancies worldwide, with an increasing annual incidence and mortality. N 7-methylguanosine (m7G) is a modification in which a methyl group is added to the seventh N position of messenger ribonucleic acid (RNA) guanine (G) by methylation transferase action. Increasing evidence revealed that m7G-related genes are closely associated with HCC development. This study aimed to develop a new m7G-related prognostic model to assess the prognosis of patients with HCC.Methods: Herein, we used RNA transcriptome sequencing and clinical data of patients with HCC from the Cancer Genome Atlas (TCGA). Patients with HCC were classified into two subtypes based on the m7G gene, and differential expression genes (DEGs) between the two types were identified. Prognostic risk models were constructed by assessing the prognostic significance of these DEGs using univariate Cox, least absolute shrinkage and selection operator, and multivariate Cox regression analyses. Functional differences were compared between the high and low-risk groups and differences in immune infiltration and immunotherapy. Finally, a preliminary pan-cancer analysis of the two genes in the model was performed.Results: Significant survival differences were found between different subtypes of patients with HCC, who were divided into high and low-risk groups according to the median risk scores. The Kaplan–Meier survival analysis showed a substantially better overall survival in the low-risk group than that in the high-risk group (p < 0.001). Receiver operating characteristic curves and within-group validation further confirmed the model’s reliability and accuracy. Additionally, significant differences were found in functional analysis, immune infiltration, and immunotherapy effects between the two groups. GAS2L3 and HTR1D have prognostic value in various cancers, which may help for subsequent studies.Conclusions: In conclusion, this prognostic model based on m7G-related genes is beneficial for individualized prognosis assessment of patients with HCC and provides a reference for clinical treatment.